Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MTPC, Biogen Partner Up on Imusera Successor
September 10, 2015
- Sanwa Kagaku, Ube to Codevelop Pruritus Treatment
September 10, 2015
- Clinical Study of JACE for Giant Pigmented Nevus Completed: J-TEC
September 9, 2015
- Sanofi Rolls Out Plaquenil, Lantus XR in Japan
September 8, 2015
- FDA Grants Breakthrough Therapy Designation to Hemophilia A Treatment ACE910: Chugai
September 7, 2015
- MSD Paid 13 Billion Yen to Doctors, Medical Institutions in 2014
September 3, 2015
- Merck Serono Japan Wants to Be Leader in Oncology, Fertility: President
September 3, 2015
- Towa to Improve Production Efficiencies and Facilities at Yamagata Plant in Response to Rising Generic Demand
September 3, 2015
- AZ, Daiichi Sankyo Team Up for Development, Commercialization of Nasal Flu Vaccine in Japan
September 3, 2015
- GSK Adjusts Shipments of Hepatitis B Treatment Tenozet Due to Disaster-Stricken Plant Following Tianjin Explosion in China
September 2, 2015
- Pfizer Japan Slapped with Biz Improvement Order over ADR Reporting
September 2, 2015
- Sanofi Names Former Keio University Professor Yuji Sato as R&D Head
September 2, 2015
- Eisai to Develop Insomnia Treatment Lemborexant with Purdue Pharma of US
September 2, 2015
- Genzyme Japan Launches Oral Gaucher’s Disease Treatment Cerdelga
September 2, 2015
- Harvoni, Yervoy, Other New Drugs Hit Japan Market
September 1, 2015
- Baxalta Japan Aims for 6-8% Annual Growth by 2020: President Kawamoto
September 1, 2015
- Merck Serono Initiates Voluntary Recall of Ovulation Inducer Serophene Due to Deviation from In-House Specifications
September 1, 2015
- GSK Paid 9.3 Billion Yen to Physicians, Medical Institutions in 2014
August 31, 2015
- Towa Raises Production Target to 14 Billion Tablets: Pres. Yoshida
August 31, 2015
- Hisamitsu Starts PII Study of Analgesic Transdermal Patch for Lower Back Pain in Japan
August 31, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…